We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADBE icon
126
Adobe
ADBE
$106B
$292K 0.01%
1,200
– –
AMZN icon
127
Amazon
AMZN
$2.84T
$282K 0.01%
1,353
-2,188
-62% -$482K
TVTX icon
128
Travere Therapeutics
TVTX
$5.85B
$264K 0.01%
8,899
+5,072
+133% +$152K
HALO icon
129
Halozyme
HALO
$11.2B
$249K 0.01%
+3,857
New +$272K
OLMA icon
130
Olema Pharmaceuticals
OLMA
$924M
$245K 0.01%
16,443
+12,541
+321% +$279K
CRSP icon
131
CRISPR Therapeutics
CRSP
$5.15B
$239K 0.01%
5,016
+3,136
+167% +$165K
TEM
132
Tempus AI
TEM
$9.39B
$224K 0.01%
4,950
+174
+4% +$9.89K
CAH icon
133
Cardinal Health
CAH
$54.1B
$182K ﹤0.01%
863
-6,806
-89% -$1.47M
PTCT icon
134
PTC Therapeutics
PTCT
$5.99B
$132K ﹤0.01%
1,935
-4,828
-71% -$342K
IQV icon
135
IQVIA
IQV
$39.1B
$126K ﹤0.01%
740
-40,527
-98% -$7.91M
ASND icon
136
Ascendis Pharma A/S
ASND
$16.2B
$123K ﹤0.01%
536
-23,794
-98% -$5.33M
ABVX
137
Abivax
ABVX
$10.4B
$117K ﹤0.01%
+1,048
New +$124K
CAI
138
Caris Life Sciences
CAI
$6.15B
$115K ﹤0.01%
6,418
– –
ARWR icon
139
Arrowhead Research
ARWR
$12.3B
$96.9K ﹤0.01%
1,545
-10,005
-87% -$633K
GOOGL icon
140
Alphabet (Google) Class A
GOOGL
$4.22T
$90.3K ﹤0.01%
314
-1,752
-85% -$550K
RYTM icon
141
Rhythm Pharmaceuticals
RYTM
$8B
$88.4K ﹤0.01%
1,016
-6,488
-86% -$631K
A icon
142
Agilent Technologies
A
$42.1B
$75.7K ﹤0.01%
664
+314
+90% +$39.8K
LH icon
143
Labcorp
LH
$25.8B
$74.7K ﹤0.01%
280
-5,389
-95% -$1.46M
NVDA icon
144
NVIDIA
NVDA
$5.45T
$71.2K ﹤0.01%
408
-3,525
-90% -$647K
MSFT icon
145
Microsoft
MSFT
$3.68T
$63.7K ﹤0.01%
172
-1,110
-87% -$464K
ZTS icon
146
Zoetis
ZTS
$30.6B
$63K ﹤0.01%
533
-196
-27% -$24.2K
BBOT
147
BridgeBio Oncology
BBOT
$734M
$62.5K ﹤0.01%
+6,982
New +$75K
INCY icon
148
Incyte
INCY
$24.3B
$45.7K ﹤0.01%
486
-4,287
-90% -$428K
MTD icon
149
Mettler-Toledo International
MTD
$28.4B
$45.4K ﹤0.01%
36
-2
-5% -$2.7K
WVE icon
150
Wave Life Sciences
WVE
$1.04B
$38.1K ﹤0.01%
5,261
-1,485,257
-100% -$19.3M
4 5
6
7 8

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.